Ask AI

Adverse Management and Supportive Care in Myelofibrosis Treatment

Selecting and sequencing JAK inhibitors in myelofibrosis requires balancing disease risk, symptom and spleen burden, cytopenias, prior treatment response, comorbidities, and patient preferences. This slideset examines evidence-based approaches to first- and later-line therapy, recognition of ruxolitinib resistance or intolerance, and transition strategies when treatment response is inadequate or adverse events limit therapy. Learners will also review practical monitoring, supportive care, and adverse event management considerations for ruxolitinib, fedratinib, pacritinib, and momelotinib to help individualize treatment, maintain clinical benefit, and reduce avoidable gaps in care.

AE Management in MF

Activity Information

Released: August 18, 2026